Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has promoted Controller Jennifer Callahan to Chief Financial Officer, succeeding longtime CFO Lou Van Horn who retired from the company in December.
Related news for (CING)
- Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)
- 24/7 Market News Snapshot 20 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)
- Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
- FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
- 24/7 Market News Snapshot 14 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)